Guest post by Surani Fernando, Acting Editor, EMEA, BioPharm Insight
BioPharm Insight‘s Clinical Activity Report (in collaboration with BioPharm Clinical) delves into the 5020 studies initiated in 1Q15 globally. While initiations saw a 30% drop, this may just indicate a slow start to the year and rates may pick up during the course of 2015. Phase II initiations continue to be the most abundant in 1Q15 (similar to 1Q14), while Phase Ib studies make a notable increase—a potential trend in companies targeting more severe diseases. Cancer continues to lead the therapeutic list of ongoing trials, while leukemia trials see the largest increase from 2014. A 44% decrease in type 2 diabetes studies could indicate industry’s acceptance of the market saturation in this area. While it’s not surprising that the US and Europe continue to dominate as regional hubs of trial activity, Egypt saw a surprise entry into the top 20, potentially offering more attractive cost efficiencies than the more popular regions.